구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Biologics |
Overview Company | Bristol-Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Crohn Disease |
Overview Indication | Spondyloarthritis (SpA) |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | targeting bone-remodeling pathway |
MoA Biomarker | biomarkers, microbiome profiling, and artificial intelligence in enabling adaptive and personalized asthma ma |
PK/PD Animal (cat.) | In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Decoding Biological Drug Names in Dermatology: The Post-2022 WHO Nomenclature Revision and Its Implications for Clinical Practice.. The WHO International Nonproprietary Names (INN) system for monoclonal antibodies underwent its most fundamental revision in 2021-2022, retiring the universal -mab suffix and replacing it with four structure-based stems (-tug, -bart, -ment, -mig). Simultaneously, new … |
Clinical Safety signal | Decoding Biological Drug Names in Dermatology: The Post-2022 WHO Nomenclature Revision and Its Implications for Clinical Practice.. The WHO International Nonproprietary Names (INN) system for monoclonal antibodies underwent its most fundamental revision in 2021-2022, retiring the universal -mab suffix and replacing it with four structure-based stems (-tug, -bart, -ment, -mig). Simultaneously, new … |
Clinical Result source | ClinicalTrials.gov NCT04458922 |
Clinical Program phase | PRECLINICAL |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT04458922 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Biologics |
Overview Company | Bristol-Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Crohn Disease |
Overview Indication | Spondyloarthritis (SpA) |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | targeting bone-remodeling pathway |
MoA Biomarker | biomarkers, microbiome profiling, and artificial intelligence in enabling adaptive and personalized asthma ma |
PK/PD Animal (cat.) | In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Decoding Biological Drug Names in Dermatology: The Post-2022 WHO Nomenclature Revision and Its Implications for Clinical Practice.. The WHO International Nonproprietary Names (INN) system for monoclonal antibodies underwent its most fundamental revision in 2021-2022, retiring the universal -mab suffix and replacing it with four structure-based stems (-tug, -bart, -ment, -mig). Simultaneously, new … |
Clinical Safety signal | Decoding Biological Drug Names in Dermatology: The Post-2022 WHO Nomenclature Revision and Its Implications for Clinical Practice.. The WHO International Nonproprietary Names (INN) system for monoclonal antibodies underwent its most fundamental revision in 2021-2022, retiring the universal -mab suffix and replacing it with four structure-based stems (-tug, -bart, -ment, -mig). Simultaneously, new … |
Clinical Result source | ClinicalTrials.gov NCT04458922 |
Clinical Program phase | PRECLINICAL |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT04458922 |
추천 비교
추천 비교